Trial Profile
Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Based Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin liposomal; Lenalidomide; Pamidronic acid; Zoledronic acid
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Apr 2018 Status changed from active, no longer recruiting to completed.
- 24 May 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2018.
- 10 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.